DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07554417

Not yet recruitingPhase 4

Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1

Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment

Assets

GLP-1 / incretin class catch-all / Semaglutide

Listed sites

1

Recruiting sites

—

Enrollment

20

estimated

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Lean mass

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07554417
Org study IDIRB-FY2026-226

Timeline

Milestones

Study start2026-04-06estimated
Study first posted2026-04-28actual
Last update posted2026-04-28actual
Primary completion2026-06-29estimated
Study completion2026-08-06estimated

Assets

Investigational agents

GLP-1 / incretin class catch-allSemaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age40 Years
Maximum age55 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Age between 40 and 55 years
•Body Mass Index (BMI) greater than 30
•Body fat percentage greater than 30% for males and 40% for females
•Android to gynoid fat ratio greater than 1.0
•Currently eligible for GLP-1 therapy
•No diagnosis of Type II diabetes

Exclusion criteria

•Presence of abnormal ECG findings, including arrhythmias or ischemic changes
•Hypertensive response to exercise, defined as systolic blood pressure exceeding 250 mmHg or diastolic pressure exceeding 115 mmHg
•Hypotensive response to exercise, defined as a drop in systolic pressure greater than 10 mmHg with increasing workload
•VO₂ max below 15 ml/kg/min
•Borg Rating of Perceived Exertion (RPE) greater than 19 during submaximal workloads
•Any contraindications to exercise as defined by ACSM guidelines
•Musculoskeletal limitations that prevent safe participation in exercise

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint
Primary/protocol endpoint

Change in Skeletal Muscle Mass

Time frame:Baseline to 12 weeks

Lean mass

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.